Secretome of human bone marrow mesenchymal stem cells: an emerging player in lung cancer progression and mechanisms of translation initiation
Oshrat Attar‐Schneider(Meir Medical Center), Maya Gottfried(Meir Medical Center), Liat Drucker(Meir Medical Center), Victoria Zismanov(Meir Medical Center)
Cited by 48
Related Papers
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
|The Lancet Oncology|2014|948
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
|Journal of Thoracic Oncology|2019|437
Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study
|European Journal of Cancer|1996|242
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
|Journal of Clinical Oncology|2018|208